Renovite – regenerative nanoclay for orthobiologic applications

Renovite — 用于骨科生物应用的再生纳米粘土

• 批准号: 10028504
• 金额: $ 88.23万
• 依托单位: RENOVOS BIOLOGICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10028504
• 关键词: Renovite; regenerative; nanoclay; orthobiologic; applications

Musculoskeletal conditions are the leading contributor to disability worldwide, with the most common and disabling conditions such as arthritis, back and neck pain, fractures and injuries. The UK currently spends over £2 bn/year on bone fractures and this cost is set to increase as the UK population ages and by 2030, it is expected that 23% of the UK population will be aged over 65\. Many bone fractures lead to orthopaedic operations that need to be repeated due to inadequate healing in approximately 10% of cases. While the prevalence of musculoskeletal conditions increases with age, younger people are also affected, often during their peak income-earning years.Current bone healing agents are very effective at stimulating new bone growth, but rely on very high doses which have been associated with some dangerous side effects such as excess bone growth outside of the skeleton, inflammation and sometimes nerve damage when used in the spine. An important limiting factor is the current inability to localise the bone agent close the site of bone repair, and its cost.Innovate UK funding has allowed Renovos, a young orthopaedic regenerative medicine company, spun out from the University of Southampton in 2017, to convert translational musculoskeletal research at the University into an exciting, innovative product, enabling the use of bone-healing agents in a more precise, localised manner, increasing their safety. This novel product, Renovite(r), based on a synthetic nanoclay biomaterial, allows use of the therapeutic agents at much lower doses for the same effect. Furthermore, because these agents are only released upon contact with cells, they can enhance healing in a more targeted manner to improve clinical outcomes with greater safety and at a lower cost.With this Innovate UK funding, Renovos will accelerate development of Renovite(r) as a therapeutic by creating further data required by the regulators in pre-clinical proof-of-concept models before the product can progress into first in-man trials. Ultimately, we anticipate our new product will provide a novel solution for tissue regeneration for bone fusion procedures and difficult-to-treat fractures, providing a range of benefits to the UK economy and for increasingly active, younger demographics requiring tissue regeneration, as well as an ageing population.

肌肉骨骼疾病是全球残疾的主要原因，最常见和致残的疾病包括关节炎、背部和颈部疼痛、骨折和受伤。英国目前每年在骨折上的花费超过20亿英镑，随着英国人口老龄化，这一成本将增加，预计到2030年，23%的英国人口将超过65岁。许多骨折导致骨科手术，由于约10%的病例愈合不充分，需要重复进行。虽然肌肉骨骼疾病的患病率随着年龄的增长而增加，但年轻人也会受到影响，通常是在他们的收入高峰期。目前的骨愈合剂在刺激新骨生长方面非常有效，但依赖于非常高的剂量，这与一些危险的副作用有关，例如骨骼外的过度生长，炎症，有时在脊柱中使用时会造成神经损伤。一个重要的限制因素是目前无法将骨修复剂定位在骨修复部位附近，以及其成本。创新英国基金允许Renovos，一家年轻的骨科再生医学公司，于2017年从南安普顿大学分拆出来，将该大学的转化肌肉骨骼研究转化为令人兴奋的创新产品，使骨愈合剂的使用更加精确，地方化，提高安全性。这种新产品Renovite（r）基于合成纳米粘土生物材料，允许以低得多的剂量使用治疗剂以获得相同的效果。此外，由于这些药物仅在与细胞接触时释放，因此它们可以更有针对性地促进愈合，从而以更低的成本提高临床疗效，同时提高安全性。有了这笔英国创新基金，Renovos将通过在临床前概念验证模型中创建监管机构所需的进一步数据，加速Renovite（r）作为治疗药物的开发，然后产品才能进入首次人体试验。最终，我们预计我们的新产品将为骨融合手术和难治性骨折的组织再生提供一种新的解决方案，为英国经济和需要组织再生的日益活跃的年轻人口以及老龄化人口提供一系列益处。